# The West Needs a Pax Biologica

> China's biomanufacturing surge threatens U.S. industrial dominance without immediate policy shifts.
- Title: The West Needs a Pax Biologica · Foreign Policy | Shortify
- Summary: China's biomanufacturing surge threatens U.S. industrial dominance without immediate policy shifts. China is displacing Western firms in biomanufacturing…
- Keywords: china, biomanufacturing, pax biologica, industrial policy, supply chain, semiconductors, pax silica, national biotechnology initiative, bipolar, West, Needs, Pax
- Source: Foreign Policy — https://foreignpolicy.com/2026/10/15/china-us-biomanufacturing-competition-industrial-policy
- Author: Lucas L. Fluegel
- Published: 2026-10-15T00:00:00+00:00
- Read time: 1 min
- Topics: china, us, biomanufacturing, pax biologica, industrial policy, supply chain, semiconductors, ai, pax silica, national biotechnology initiative, bipolar
## The West Needs a Pax Biologica
Chinese firms are displacing Western competitors in one of the century’s most important and most overlooked industries.
## U.S. Manufacturing Misstep
Every U.S. politician wants to reinvigorate manufacturing, but most are chasing a 2.0-century version of it.
## Biomanufacturing Defined
Biomanufacturing uses biological systems to make goods, from beer to mRNA vaccines.
## China’s Industrial Leap
China has positioned itself to leapfrog the U.S. in biomanufacturing through state-directed investment.
## Glufosinate Case Study
Chinese firms captured 75% price drop in glufosinate herbicide market by shifting from chemical to biological production.
## U.S. Policy Fragmentation
U.S. has fragmented industrial policy with $1 billion Pentagon investment versus China’s $4 billion in 2024.
## Global Supply Chain Risks
U.S. firms rely on German equipment, Japanese consumables, and South Korean/Swiss production capacity.
## Pax Silica Precedent
U.S. launched Pax Silica initiative with $250 million fund and trade coordination for AI supply chains.
## Pax Biologica Proposal
A Pax Biologica initiative could unite Germany, Switzerland, Japan, South Korea, UK, and EU for biomanufacturing.
## Regulatory Fragmentation
Global regulatory differences delay biomanufacturing scaling by years and increase financial burdens.
## China’s Strategic Move
China explicitly frames biomanufacturing standards as securing its global economic competitiveness.
## U.S. Regulatory Gaps
U.S. lacks harmonized standards for biomanufacturing, hindering international scaling of products.
## Critical Next Step
Harmonizing global biomanufacturing standards is essential for Western supply chain resilience.
## U.S. Industrial Risk
Without coordinated action, U.S. will cede biomanufacturing leadership to China.
## Key takeaway

China is displacing Western firms in biomanufacturing, risking U.S. supply-chain independence without coordinated international action.